The potential mechanism is that bortezomib upregulates miR-198 in DLBCL, and then miR-198 combines with the 3'-UTR of AT-hook 1 to inhibit the expression of HMGA1, thus inhibiting the proliferation and migration of DLBCL cells 114. The gene discussed is HMGA1; the disease is diffuse large B-cell lymphoma.